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Abstract
Background: Homeodomain-interacting protein kinase-2 (HIPK2), a transcriptional co-repressor
with apoptotic function, can affect hypoxia-inducible factor 1 (HIF-1) transcriptional activity,
through downmodulation of its HIF-1α subunit, in normoxic condition. Under hypoxia, a condition
often found in solid tumors, HIF-1α is activated to induce target genes involved in chemoresistance,
inhibition of apoptosis and tumor progression. Here, we investigated whether the HIPK2
overexpression could downregulate HIF-1α expression and activity in tumor cells treated with
hypoxia-mimicking condition, and evaluated whether HIPK2-dependent downregulation of HIF-1α
could sensitize chemoresistant tumor cells to adriamycin (ADR)-induced apoptosis.
Methods: Tumor cell lines carrying wild-type p53, siRNA p53, or mutant p53 were overexpressed
with HIPK2 (full length or catalytic inactive mutant) and treated with cobalt chloride (CoCl2) to
mimic hypoxia, in the presence or absence of ADR treatment. HIF-1α expression was measured
by semiquantitative reverse-transcriptase (RT)-PCR and Western immunoblotting and HIF-1
activity was evaluated by luciferase assay using reporter plasmid containing hypoxia response
elements (HREs) upstream of luciferase gene. HIF-1 target genes, including multidrug resistance 1
(MDR1) and the antiapoptotic Bcl2 were determined by RT-PCR. Cell survival and apoptosis were
measured by colony assay and cleavage of the caspase-3 substrate PARP, respectively.
Results:  Overexpression of HIPK2 resulted in downmodulation of cobalt-stabilized HIF-1α
protein and HIF-1α mRNA levels, with subsequent inhibition of HIF-1 transcriptional activity.
MDR1 and Bcl-2 gene expression was downmodulated by HIPK2 overexpression in cobalt-treated
cells. Inhibition of HIF-1 transcriptional activity was dependent on HIPK2 catalytic activity. HIPK2
overexpression did not induce per se apoptosis of cobalt-treated cells, on the contrary it sensitized
cobalt-treated cells to ADR-induced apoptosis, regardless of their p53 status.
Conclusion: The ability of HIPK2 to restore the apoptosis-inducing potential of chemotherapeutic
drug in hypoxia-mimicking condition and therefore to sensitize chemoresistant tumor cells suggests
that HIPK2 may induce fundamental alterations in cell signaling pathways, involving or not p53
function. Thus potential use of HIPK2 is promising for cancer treatment by potentiating cytotoxic
therapies, regardless of p53 cell status.
Published: 7 January 2009
Molecular Cancer 2009, 8:1 doi:10.1186/1476-4598-8-1
Received: 4 November 2008
Accepted: 7 January 2009
This article is available from: http://www.molecular-cancer.com/content/8/1/1
© 2009 Nardinocchi et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Cancer 2009, 8:1 http://www.molecular-cancer.com/content/8/1/1
Page 2 of 9
(page number not for citation purposes)
Background
Homeodomain-interacting protein kinase-2 (HIPK2) is a
serine/threonine kinase [1] that as been shown to be
involved in restraining tumor progression. HIPK2 carries
out its potential oncosuppressor function through both
its catalytic and transcriptional co-repressor activities. We
and others have found that HIPK2 phosphorylates p53 at
serine 46 (Ser46) after severe DNA damage and induces
apoptosis [2,3]; we also found that silencing of HIPK2
inhibits p53 transcriptional activity [4], inhibits drug-
induced apoptosis inducing chemoresistance [5], and
increases genomic instability [6], moreover, we showed
that HIPK2 ovrexpression circumvents the blockade of
apoptosis in cisplatin-resistant cells, restoring the p53-
dependent apoptosis [7]. The role of HIPK2 in regulating
tumor growth has been also evidenced in p53-independ-
ent manner. We have shown that HIPK2 downregulates
the cPLA2-induced prostaglandin E2 (PGE2) production,
and that HIPK2 silencing increases in vivo tumor growth
and tumor vascularity [8,9]. Thus, we have found that
HIPK2 can suppress the β-catenin-mediated transcrip-
tional activation of vascular endothelial growth factor
(VEGF) [10]. Furthermore, we have recently found that
HIPK2 binds to the hypoxia-inducible factor 1α (HIF-1α)
promoter, in a co-repressor complex with histone deacety-
lase 1 (HDAC1), to repress HIF-1α at transcriptional level
with subsequent suppression of HIF-1 transcriptional
activity, in normoxic condition [9].
HIF-1 is a heterodimeric transcription factor that transac-
tivates more than 60 target genes involved in multiple
aspects of tumorigenesis including tumor growth, angio-
genesis, metastasis, and chemotherapy response [11].
HIF-1 consists of two subunits, HIF-1α and HIF-1β [12]:
HIF-1β is constitutively expressed in cells, while HIF-1α
stability is stimulated by hypoxia, growth factors, and sev-
eral oncogenes [13] thus, HIF-1α is overexpressed in
many types of tumors and contributes to chemoresistance
[14]. Activation of HIF-1 depends primarily upon redox-
sensitive stabilization of its α subunit [15] however, HIF-
1 responsive genes can be induced by cobalt ions with
kinetics similar to that of hypoxia induction [16].
The mechanisms of chemoresistance appear to be multi-
factorial and include, among others, inhibition of apopto-
sis and dysfunction of p53 oncosuppressor [17]. Growing
evidence suggests that hypoxia in tumors selects for cells
with decreased potential for apoptosis through for
instance the overexpression of the antiapoptotic gene Bcl-
2 and decreased killing effect through upregulation of
drug transporter proteins that may contribute to resistance
to standard radio- and chemo-therapy [11,18]. Thus,
multidrug resistance (MDR) is a serious obstacle for can-
cer chemotherapy [19]. The MDR phenotype is associated
with induction of the MDR1 gene [20] which encodes for
P-glicoprotein a transporter protein able to extrude a
range of anti-cancer drugs out of the cell, lowering their
concentration below the level required for cytotoxic
effects [14]. MDR1 has been shown to be HIF-1 target
gene [21] and is involved in the acquisition of multidrug
resistance in various types of cancers cells, for instance,
tumors resistance to doxorubicin is associated with
increased levels of MDR1 gene [19].
A recent survey of malignant and normal tissues found
that the expression of HIF-1α is commonly increased in a
variety of human tumors including colorectal carcinoma
and glioblastoma [22]. The purpose of our investigation
was to evaluate, in colon cancer and glioblastoma cell
lines, whether HIPK2 might inhibit HIF-1α expression
and activity in hypoxia-mimicking condition and sensi-
tize chemoresistant tumor cells to adriamycin (ADR)-
induced apoptosis. The results show that overexpression
of HIPK2 inhibited HIF-1α mRNA levels and cobalt-stabi-
lized HIF-1α protein, with subsequent suppression of
HIF-1 transcriptional activity. The HIPK2-mediated inhi-
bition of HIF-1α correlated with suppression of MDR1
and Bcl-2 gene transcription and with sensitization of
cobalt treated-tumor cells, regardless of their p53 status,
to ADR-induced apoptosis. Thus, HIPK2 could be useful
in cancer therapy to enhance the effectiveness of chemo-
therapeutic drugs.
Results
HIPK2 downregulates HIF-1α expression and protein 
levels in hypoxia-mimicking condition
To address whether HIPK2 might regulate the HIF-1α
expression induced by hypoxia, tumor cells were treated
with cobalt chloride (CoCl2) that stabilizes HIF-1α and
induces HIF-1 responsive genes with kinetics similar to
that of hypoxia [16]. RKO colon cancer cells, carrying
wild-type p53, stably transfected with siRNA control vec-
tor (RKO-C) or with siRNA p53 vector (RKO-p53i), and
T98G glioblastoma cells, carrying mutant p53, were trans-
fected with HIPK2 or its catalytic inactive mutant K221R.
After transfection, cells were treated with CoCl2 (200 μM)
for 24 h. As shown in Fig. 1A, HIPK2 overexpression
downmodulated HIF-1α mRNA levels while the K221R
mutant failed to do so. HIF-1α mRNA expression levels
were not induced by cobalt treatment, as expected. Fur-
thermore, the cobalt-stabilized HIF-1α protein levels were
strongly suppressed by HIPK2 overexpression, compared
to the K221R kinase inactive mutant in all three cell lines
analyzed (Fig. 1B). Then, the HIF-1α protein half-life was
evaluated after HIPK2 overexpression. RKO-C cells were
transfected with either HIPK2 expression vector or the
empty vector and 24 h later exposed to cobalt treatment to
induce HIF-1α accumulation. Thereafter (t = 0), the syn-
thesis of HIF-1α protein was inhibited by the addition of
cycloheximide (CHX) and the degradation of the cobalt-Molecular Cancer 2009, 8:1 http://www.molecular-cancer.com/content/8/1/1
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stabilized HIF-1α protein was monitored for a further
period of 180 min. As shown in Fig. 1C, HIPK2 was able
to accelerate the degradation of cobalt-stabilized HIF-1α,
compared to the empty vector-transfected cells. Densito-
metric analysis of protein expression show that the HIF-
1α half-life after transfection with the empty vector was of
about 120 min and drop down to about 80 min after
HIPK2 overexpression (Fig. 1D). These data suggest that
HIPK2 downmodulated HIF-1α mRNA and protein levels
under hypoxia-mimicking condition and that the HIPK2
catalytic activity was involved in this regulation.
HIPK2 inhibited the HIF-1α transcriptional activity of 
target genes
Next, the function of HIF-1 pathway was investigated by
using a transient reporter assay in which endogenous HIF-
1 binds hypoxia response elements (HREs) of erythropoi-
etin gene promoter cloned upstream of a luciferase tran-
scriptional reporter (pEpoE-luc); a vector containing the
mutated HIF-1 binding site (pEpoEM1-luc) was also eval-
uated [15]. To this end, H1299 cells were co-transfected
with pEpoE-luc or pEpoEM1-luc reporters and HIPK2 or
K221R expression vectors. After transfection cells were
treated with CoCl2 for 24 h. As shown in Fig. 2A, overex-
pression of HIPK2 markedly suppressed the cobalt-induc-
tion of luciferase gene expression. Moreover, this effect
correlated with the HIPK2 catalytic activity. HIPK2 did not
affect the activity of the pEpoEM1-luc reporter that was
neither induced by cobalt-treatment (Fig. 2A). Thus, the
effect of HIPK2 on luciferase gene expression was HIF-1-
dependent.
HIPK2 downregulated HIF-1a expression and protein levels in hypoxia-mimicking condition Figure 1
HIPK2 downregulated HIF-1a expression and protein levels in hypoxia-mimicking condition. (A), RKO-C, RKO-
p53i, and T98G cells were transfected with HIPK2-GFP or K221R-GFP expression vectors. Twelve hours after transfection 
cells were treated with CoCl2 (200 μM) for 24 h. Thirty-six hours after transfection cells were harvested and HIF-1α expres-
sion was determined by RT-PCR analysis (Total time treatments: 36 h transfection, 24 h CoCl2). Aldolase (aldo) was used as 
loading control. One representative experiment from three independent experiments is shown. (B), Nuclear extracts from 
cells treated as in (A) were analyzed by Western immunoblotting with anti-HIF-1α antibody. Anti-Hsp70 was used as protein 
loading control. (C), RKO-C cells were transfected with HIPK2-GFP or GFP-empty vectors. Twelve hours after transfection 
cells were treated with CoCl2 (200 μM) for 20 h before adding cycloheximide (CHX) (40 μg/ml, t = 0). Nuclear extracts were 
analyzed by Western immunoblotting 60, 120, and 180 minutes following CHX treatment, with anti-HIF-1α antibody. Anti-
Hsp70 was used as protein loading control. (D), The relative amount of HIF-1α protein levels from panel (C) was quantitated 
by densitometric analysis and plotted. The half-life of HIF-1α is shown by dotted lines.Molecular Cancer 2009, 8:1 http://www.molecular-cancer.com/content/8/1/1
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Next we evaluated whether HIPK2 could suppress HIF-1
target gene transcription. To this aim, RKO-C, RKO-p53i,
and T98G cells were transfected with HIPK2 or K221R and
soon after transfection treated with CoCl2 for 24 h. Semi-
quantitative RT-PCR analysis of mRNA levels showed that
the MDR1 and Bcl2 gene induction in cobalt treated-RKO-
C cells was strongly suppressed by HIPK2 overexpression
but not by K221R mutant (Fig. 2B). On the other hand,
the already elevated MDR1 and Bcl2 mRNA levels in RKO
p53i and in T98G cells, compared to RKO-C cells, were
not further increased by cobalt treatment, at least at the
time point analyzed; however, they were strongly sup-
pressed by HIPK2 overexpression (Fig. 2B). Altogether,
these results indicate that HIPK2 inhibited HIF-1 tran-
scriptional activity, in cobalt-treated cells, suppressing
MDR1 and Bcl2 gene expression.
Effect of HIPK2 on cell death and survival after cobalt 
treatment
Next we evaluated whether HIPK2 overexpression could
affect cell death and survival of cobalt-treated cells. To this
aim, RKO-C, RKO-p53i and T98G cells were transfected
with HIPK2-GFP and K221R-GFP expression vectors and
soon after transfection treated with cobalt. The GFP detec-
tion by fluorescence microscope allowed to monitor
transfection efficiency that was comparable between
HIPK2 and K221R expression vectors and among the
three cell lines. Cell viability was then determined by
Trypan blue exclusion 24 h later. As shown in Fig. 3A,
HIPK2 induced cell death, compared to K221R, in cobalt-
treated cells, ranging from 10% (in p53i and T98G cells)
to 20% (in RKO-C cells). However, long-term analysis of
cell survival show that HIPK2 overexpression did not
reduce colony-forming ability of the cobalt-treated cells
(Fig. 3B). The effect of hypoxia-mimicking condition on
survival after HIPK2 overexpression was highly reproduc-
ible in three different experiments. We have previously
shown that HIPK2 strongly decreases colony formation of
RKO cells compared to K221R transfection, inducing p53-
dependent apoptosis, furthermore, HIPK2 does not sup-
press colony formation in either p53 mutant or null cells
[2]. Therefore, these data suggest that HIPK2 was able to
induce transient cell death in cobalt-treated cells, thus, it
did not induce long-lasting cell death, as seen by colony
assay, neither apoptosis (see below).
HIPK2 sensitizes chemoresistant cells to ADR-induced 
apoptosis in hypoxia-mimicking condition
In the previous paragraphs we have shown that HIPK2
might change the transcriptional potential of HIF-1 in
cobalt-treated cells although it did not induce long-term
cell death. Therefore, we asked whether HIPK2 could sen-
sitize cobalt-treated cells to drug-induced apoptosis. To
this aim, RKO-C, RKO-p53i, and T98G cells were trans-
fected with HIPK2 expression vector; soon after transfec-
tion cells were trypsinized, counted and equal cell
numbers were re-plated in triplicate prior to the exposure
of cells to CoCl2  and ADR alone or in combination.
Twenty-four hours later, cell viability was assayed by
HIPK2 inhibited HIF1 transcriptional activity of target genes Figure 2
HIPK2 inhibited HIF1 transcriptional activity of tar-
get genes. (A), H1299 cells were transiently co-transfected 
with HIPK2-GFP or K221R-GFP expression vectors along 
with the luciferase reporter gene driven by human erythro-
poietin enhancer region containing a functional HIF-1 binding 
site (pEpoE-luc) or a mutant HIF-1 binding site (pEpoEM1-
luc). Twelve hours after transfection cells were treated with 
CoCl2 (200 μM) for 24 h. Thirty-six hours after transfection 
luciferase activity was assayed. Relative Luciferase Units 
(RLU) normalized to β-gal is shown. The shown data repre-
sent the mean ± SD from three independent experiments 
performed in duplicate. (B), RKO-C, RKO-p53i, and T98G 
cells were transfected with HIPK2-GFP or K221R-GFP 
expression vectors. Twelve hours after transfection cells 
were treated with CoCl2 (200 μM) for 24 h. Thirty-six hours 
after transfection cells were harvested and MDR1 and Bcl2 
expression was determined by RT-PCR analysis. Aldolase 
(aldo) was used as loading control. One representative 
experiment from three independent experiments is shown.Molecular Cancer 2009, 8:1 http://www.molecular-cancer.com/content/8/1/1
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Trypan blue exclusion. As shown in Fig. 4A, exposure to
CoCl2 strongly reduced the ADR-induced cell death of
RKO-C cells, while did not further change the viability of
ADR-treated RKO-p53i and T98G cells. Interestingly,
HIPK2 overexpression significantly restored the ADR-
induced cell apoptosis in cobalt-treated RKO-C cells, as
shown by cell viability (Fig. 4A) and Western immunob-
lotting of cleavage of the caspase-3 substrate PARP (Fig.
4B). It is noteworthy that HIPK2 significantly sensitized to
ADR-induced apoptosis also the RKO-p53i and T98G cells
(Fig. 4A, 4B) that showed an inherent ADR resistance in
anoxic condition (Fig. 4A) and also resistance to HIPK2-
induced long-term cell death (Fig. 3B). Moreover, semi-
quantitative RT-PCR analysis of mRNA levels showed that
ADR treatment did not change the HIF-1α, MDR1, and
Bcl2 gene expression in cobalt-treated RKO-C, p53i, and
T98G cells, on the other hand, HIPK2 overexpression
strongly reduced HIF-1α, MDR1, and Bcl2 gene expres-
sion (Fig. 4C). The biological outcome of HIPK2 overex-
pression in cobalt-treated cells, in the presence or absence
of ADR was further evaluated by colony forming assay. To
this aim, RKO-p53i and T98G cells were transfected with
HIPK2 expression vector; soon after transfection cells were
treated with cobalt (200 μM) for 24 h before adding 2 h
pulse of ADR (2 μg/ml). Cells were then trypsinezed,
counted and equal number of cells were re-plated in
duplicate in fresh medium and kept in culture for at least
ten days. As shown in Fig. 4D, colony forming ability of
RKO-C, p53i, and T98G cells treated with combination of
cobalt and ADR was markedly suppressed by HIPK2 over-
expression, while ADR only partially limited cell growth
of cobalt-treated cells. ADR alone strongly suppresses col-
ony formation only in RKO-C cell, as expected (Fig. 4D).
Altogether, these data strongly suggest that HIPK2 could
reverse cobalt-induced cell chemoresistance of wild-type
p53 RKO-C cells and sensitize chemoresistant RKO-p53i
and mutant p53 T98G cells to ADR-induced apoptosis.
This biological outcome correlated with suppression of
MDR1 and Bcl2 gene expression.
Discussion
Our studies provide a rationale for the potential use of
HIPK2 transduction to sensitize chemosensitive tumor
cells to ADR-induced apoptosis. We show that HIPK2
downregulated HIF-1α levels in hypoxia-mimicking con-
dition, suppressing HIF-1 transcriptional activity. Thus,
HIF-1 target genes such as MDR1 and Bcl-2 were down-
modulated by HIPK2 overexpression in cobalt-treated
cells: downmodulation of HIF-1α, MDR1, and Bcl2 corre-
lated with ADR-induced apoptosis. Thus, HIPK2 overex-
pression did not induce per se apoptosis of cobalt-treated
cells, on the contrary it sensitized cobalt-treated cells to
ADR-induced apoptosis, regardless of their p53 status.
We have previously documented the role of HIPK2 in
drug-induced apoptosis. HIPK2 activation by chemother-
apeutic drugs, including ADR and cisplatin, results in p53
phosphorylation at Ser46 with specific induction of apop-
tosis [4,5]; on the other hand, HIPK2 is unable to induce
apoptosis in p53 mutant cells [2], although p53-inde-
pendent apoptotic pathways activated by HIPK2 have
Effect of HIPK2 on cell death and survival after cobalt treat- ment Figure 3
Effect of HIPK2 on cell death and survival after cobalt 
treatment. RKO-C, RKO-p53i, and T98G cells were trans-
fected with HIPK2-GFP or K221R-GFP expression vectors. 
Twelve hours after transfection cells were treated with 
CoCl2 (200 μM) for 24 h. Thirty-six hours after transfection 
cells cell viability was assayed by Trypan blue exclusion. The 
results shown are representative of three independent 
experiments performed in duplicate. (B) Colony-forming abil-
ity of RKO-C, RKO-p53i, and T98G cells transfected and 
treated as in (A). Death-resistant colonies were stained with 
crystal violet 14 days after transfection.Molecular Cancer 2009, 8:1 http://www.molecular-cancer.com/content/8/1/1
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been reported [23-25]. We have recently shown that
HIPK2 deregulation is involved in chemoresistance how-
ever, HIPK2 overexpression circumvents the blockade of
apoptosis in chemoresistant cells, restoring activation of
p53Ser46 and the caspases' pathway [7]. Therefore, lack of
functional p53 contributes to resistance to HIPK2 apop-
totic function although, deregulation of the upstream sig-
naling pathways and of the regulatory proteins that finally
lead to HIPK2 activation in response to different stimuli
cannot be excluded.
In the present study, we have shown that the exogenous
HIPK2 might enhance the ADR-apoptotic response
impaired by hypoxia-mimicking condition. It is notewor-
HIPK2 sensitized resistant cells to ADR-induced apoptosis, in hypoxia-mimicking condition Figure 4
HIPK2 sensitized resistant cells to ADR-induced apoptosis, in hypoxia-mimicking condition. (A), RKO-C, RKO-
p53i, and T98G cells were transfected with HIPK2-GFP, and the empty GFP vector. Twelve hours after transfection cells were 
pre-treated with CoCl2 (200 μM) for 8 h and then treated with and ADR (2 μg/ml) for 24 h (Total time treatments: 36 h trans-
fection, 24 h ADR; 32 h CoCl2). Both floating and adherent cells were collected and cell viability was determined by Trypan 
blue exclusion. The results shown are representative of three independent experiments performed in duplicate. *p 0.001. (B), 
RKO-C, -p53i, and T98G cells were treated as in (A) and nuclear cell extracts analyzed by Western immunoblotting with anti-
PARP antibody. The cleaved form of PARP is shown. Anti-Hsp70 was used as protein loading control. (C), RKO-C, RKO-p53i, 
and T98G cells transfected and treated as in (A) were analyzed by RT-PCR analysis for HIF-1α, MDR1, and Bcl2 expression. 
Aldolase (aldo) was used as loading control. One representative experiment from three independent experiments was shown. 
(D), Colony-forming ability of RKO-C, RKO-p53i, and T98G cells transfected with HIPK2-GFP and pre-treated with CoCl2 for 
22 h and ADR (2 μg/ml) for 2 h (Total time treatments: 24 h CoCl2 and 2 h ADR). Death-resistant colonies were stained with 
crystal violet 10 days after transfection.Molecular Cancer 2009, 8:1 http://www.molecular-cancer.com/content/8/1/1
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thy that HIPK2 sensitized to ADR-induced apoptosis also
the RKO-p53i and T98G cells (carrying mutant p53) that
showed an inherent ADR resistance in anoxic condition
(Fig. 4A) and also resistance to HIPK2-induced long-term
cell death (Fig. 3B). These data suggest that HIPK2 might
induce fundamental alterations in cell signaling path-
ways, involving or not p53-dependent apoptotic function.
In this regard, we have recently found that HIPK2 down-
modulates HIF-1α expression in normoxic condition,
repressing HIF-1 transcriptional activity [9]. HIF-1α is a
negative factor for tumor therapy that has a powerful role
in modulating chemotherapeutic responses [26]. The
expression of multidrug resistance (MDR) via HIF-1-
dependent regulation has been shown to increase chem-
oresistance [21]. Our results showed that overexpression
of HIPK2 downmodulated HIF-1α expression and HIF-1
transcriptional activity, in hypoxia-mimicking condition.
Blocking of HIF-1α expression abolished MDR1 and Bcl2
expression and restored ADR-induced apoptosis. Reversal
of MDR1 and Bcl2 upregulation could therefore provide
the mechanistic basis for chemosensitization observed
during HIPK2 transduction.
In summary, this study shows the efficacy of HIPK2 trans-
duction to restore the apoptosis-inducing potential of
chemotherapeutic drug in hypoxia-mimicking condition
and therefore to sensitize chemoresistant tumor cells,
regardless of their p53 status.
Conclusion
We present here a potential approach of combining
HIPK2 transduction with chemotherapeutic drug for the
treatment of chemoresistant tumor cells. Specifically,
HIPK2 restored the apoptosis-inducing potential of chem-
otherapeutic drug in hypoxia-mimicking condition and
sensitized chemoresistant tumor cells. These data suggest
that HIPK2 might induce fundamental alterations in cell
signaling pathways, involving or not p53 function and
provide a foundation for the development of combined
regimens that would enhance the apoptotic response of
chemoresistant cells. Thus potential use of HIPK2, by
either gene therapy deliver or identification of small pep-
tides able to activate HIPK2, is promising for cancer treat-
ment by potentiating cytotoxic therapies, regardless of
p53 cell status.
Methods
Cell cultures and treatments
Human colon carcinoma RKO (carrying wtp53), RKO-
p53-interfered (p53i) (a kind gift of Silvia Soddu, Regina
Elena Cancer Institute, Rome Italy), the human glioblast-
oma T98G (mutant p53, codon 237 methionine-to-iso-
leucine change) [27], and human lung adenocarcinoma
H1299 cells were cultured in RPMI-1640 (GIBCO-BRL,
Life Technology, Grand Island, NY, USA) supplemented
with 10% heat-inactivated fetal bovine serum (GIBCO-
BRL) plus glutamine and antibiotics in humidified atmos-
phere with 5% CO2 at 37°C.
Adriamycin (ADR) was diluted into the medium to a final
concentration of 2 μg/ml that we have shown can induce
apoptosis in wild-type bearing cells but not in p53 inac-
tive cells [4], for 16-24 h; hypoxia-mimicking condition
was obtained by adding cobalt chloride (CoCl2) into the
culture medium to a final concentration of 200 μM [16]
for 24 h; cycloheximide (CHX), the inhibitor of protein
synthesis, was diluted into the medium to a final concen-
tration of 40 μg/ml for 3 h.
RNA extraction and semiquantitative reverse-
transcriptase (RT)-PCR analysis
Cells were transfected with HIPK2-GFP, K221-GFP coding
HIPK2 kinase defective mutant [2], and the empty GFP
vector using LipofectaminePlus method. Soon after trans-
fection cells were trypsinized, counted and equal cell
number re-plated in 60 mm Petri dishes. Twelve hours
after transfection cells were pre-treated with CoCl2 (200
μM) for 8 h and then treated with and ADR (2 μg/ml) for
16 h. Thirty-six hours after transfection, cells were har-
vested in TRIzol Reagent (Invitrogen) and total RNA was
isolated following the manufacturer's instructions. The
first strand cDNA was synthesized according to the manu-
facturer's instructions (Moloney murine leukemia virus
reverse transcriptase kit, Applied). Semi-quantitative RT-
PCR was carried out by using HOT-MASTER Taq (Eppen-
dorf) with 2 μl cDNA reaction and genes specific oligonu-
cleotides under conditions of linear amplification. The
sequence of the primers used for RT-PCR was as follow:
HIF-1α forward: 5'-CAGAAGATACAAGTAGCCTC-3';
HIF-1α reverse: 5'-CTGCTGGAATACTGTAACTG-3';
MDR1 forward: 5'-AACGGAAGCCAGAACATTCC-3';
MDR1 reverse: 5'-AGGCTTCCTGTGGCAAAGAG-3'; Bcl-2
forward: 5'-AGGA TTGTGGCCTTCTTTGAG-3'; Bcl-2
reverse: 5'-GAGACAGCCAGGAGAAATCAAA-3'. DNA
products were run on 2% agarose gel and visualized by
ethidium bromide using UV light. Densitometric analyses
was applied to quantify mRNA levels. Data presented are
representative of at least three independent experiments.
Viability assay and colony assay
Cells were transfected with HIPK2-GFP, K221-GFP and
the empty GFP vector using LipofectaminePlus method
(Invitrogen Corp., Carlsband, CA, USA). Soon after trans-
fection cells were trypsinized, counted and equal cell
number re-plated in triplicate in 60 mm Petri dishes.
Twelve hours after transfection cells were pre-treated with
CoCl2 (200 μM) for 8 h and then treated with and ADR (2
μg/ml) for 24 h. Both floating and adherent cells were col-
lected and cell viability was determined by Trypan blueMolecular Cancer 2009, 8:1 http://www.molecular-cancer.com/content/8/1/1
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exclusion by direct counting with a haemocytometer, as
reported [5].
For colony-formation assay, cells were transfected with
expression vectors as above and soon after transfection
treated with CoCl2 (200 μM) for 22 h before adding a
pulse of ADR (2 μg/ml) for 2 h. After treatments, cells
were washed, trypsinized, counted and equal cell number
re-plated in duplicate with fresh medium, in 60 mm Petri
dishes. Death-resistant colonies were stained with crystal
violet 10-4 days later. Data presented are representative of
at least three independent experiments.
Transfection, plasmids, and transactivation assay
Transient transfection was carried out using H1299 cells
and the cationic polymer LipofectaminePlus method
(Invitrogen Corp., Carlsband, CA, USA) according to
manufacturers' instructions. The amount of plasmid DNA
was equalized in each sample by supplementing with
empty vector. Cells were transiently co-transfected with
HIPK2-GFP or K221R-GFP expression vectors along with
the luciferase reporter gene driven by human erythropoie-
tin enhancer region containing a functional HIF-1 bind-
ing site (pEpoE-luc) or a mutant HIF-1 binding site
(pEpoE-mut-luc) [15] (kindly provided by L. Eric Huang,
N.C.I., N.I.H, Bethesda, MA, USA). Soon after transfection
cells were trypsinized, counted and equal cell number re-
plated in 60 mm Petri dishes. Twelve hours after transfec-
tion cells were pre-treated with CoCl2 (200 μM) for 8 h
and then treated with and ADR (2 μg/ml) for 16 h. Trans-
fection efficiency was normalized with the use of a co-
transfected  β-galactosidase (β-gal) plasmid. Thirty-six
hours after transfection, cells were harvested and luci-
ferase activity was assayed on whole cell extract. Luciferase
values were normalized to β-galactosidase activity and
protein content. At least three independent experiments
were performed in duplicate.
Western blot analysis
Total cell extracts were prepared by incubating at 4°C for
30 min in lysis buffer (50 mM Tris-HCl, pH 7.5, 50 mM
NaCl, 5 mM EDTA, 150 mM KCl, 1 mM dithiothreitol, 1%
Nonidet P-40) plus a mix of protease and phosphatase
inhibitors (Sigma Chemical Company, MO, USA).
Nuclear extracts were prepared essentially as described
[28]. Proteins were then separated by 9% SDS-PAGE and
blotted onto nitrocellulose (BioRad, CA, USA). The mem-
branes were probed with a primary antibody followed by
with horseradish-peroxidase conjugated secondary anti-
body. The antibodies used were: monoclonal anti-HIF-1α
(Novus Biologicals, UCS Diagnostic, Italy), monoclonal
anti-poly(ADP-ribose) polymerase (PARP, BD Pharmin-
gen, CA, USA), and monoclonal anti-Hsp70 (Stressgene,
BC, Canada). Immunoreactivity was detected with the
Advanced-ECL chemoluminescence reaction kit (Amer-
sham., IL, USA).
Statistics
Continuous variables were analyzed by the Student t test.
Data are expressed as mean ± SD. A value of p ≤ 0.05 was
considered statistically significant.
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